CD73-adenosine: a next-generation target in immuno-oncology

被引：114

作者：

Allard, David ^{[1
,2
,3
]}

Allard, Bertrand ^{[1
,2
,3
]}

Gaudreau, Pierre-Olivier ^{[1
,2
,3
]}

Chrobak, Pavel ^{[1
,2
,3
]}

Stagg, John ^{[1
,2
,3
]}

机构：

[1] Ctr Hosp Univ Montreal, Ctr Rech, Montreal, PQ, Canada

[2] Inst Canc Montreal, Montreal, PQ, Canada

[3] Univ Montreal, Fac Pharm, Montreal, PQ H3C 3J7, Canada

来源：

IMMUNOTHERAPY | 2016年 / 8卷 / 02期

关键词：

adenosine; adenosine receptors; anti-tumor immunity; CD73; immune checkpoint; HUMAN BREAST-CANCER; CHRONIC LYMPHOCYTIC-LEUKEMIA; SUPPRESSES TUMOR-GROWTH; REGULATORY T-CELLS; EXTRACELLULAR ADENOSINE; ECTO-5'-NUCLEOTIDASE CD73; OVARIAN-CANCER; CLINICAL-SIGNIFICANCE; PROGNOSTIC BIOMARKER; ANTITUMOR-ACTIVITY;

D O I：

10.2217/imt.15.106

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

071005 [微生物学]; 100108 [医学免疫学];

摘要：

Cancer immunotherapy has entered in a new era with the development of first-generation immune checkpoint inhibitors targeting the PD1/PD-L1 and CTLA-4 pathways. In this context, considerable research effort is being deployed to find the next generation of cancer immunotherapeutics. The CD73-adenosine axis constitutes one of the most promising pathways in immuno-oncology. We and others have demonstrated the immunosuppressive role of CD73-adenosine in cancer and established proof-of-concept that the targeted blockade of CD73 or adenosine receptors could effectively promote anti-tumor immunity and enhance the activity of first-generation immune checkpoint blockers. With Phase I clinical trials now underway evaluating anti-CD73 or anti-A2A therapies in cancer patients, we here discuss the fundamental, preclinical and clinical findings related to the role of the CD73-adenosinergic pathway in tumor immunity.

引用

页码：145 / 163

页数：19

共 164 条

[1]

Ectonucleoside triphosphate diphosphohydrolase-1 (E-NTPDase1/CD39) as a new prognostic marker in chronic lymphocytic leukemia [J].